Conditioning with targeted busulfan for autologous peripheral blood stem cells transplantation for acute myelogenous leukemia in an XYY male

Abstract

We report herein a 19-year-old Japanese male with XYY syndrome who developed acute myelogenous leukemia. During three courses of cytotoxic chemotherapy, he suffered repeated hepatic and renal insufficiencies, possibly related to latent dysfunction from the XYY syndrome. The patient was treated with granulocyte colony-stimulating factor combined with etoposide, cytarabine, and busulfan (the latter adjusted to a targeting dose) followed by autologous peripheral blood stem cell transplantation. He had no severe regimen-related toxicities and is now free of leukemia. Am.

Acute promyelocytic leukaemia with a PML-RARA insertional translocation and a chromosome 21 abnormality in XYY syndrome: Case report

“…As a result of the fact that the XYY syndrome involves multiple organ dysfunction, toxicity from chemotherapy can be severe. 13,14 However, the case described in this current report underwent each course of chemotherapy without experiencing severe side-effects. Therefore, the authors recommend that the sequential strategy is appropriate for patients with XYY syndrome and APL, as it was associated with good clinical outcomes and few side-effects.…”

“…1 A few haematological malignancies have been reported in patients with XYY syndrome, occurring in acute myeloid leukaemia without maturation, acute myeloid leukaemia with maturation, chronic myeloid leukaemia, and acute lymphoblastic leukaemia. [13][14][15][16][17] To the best of our knowledge, this is the first case reporting a patient with 47,XYY syndrome with APL. The male patient described in this current case report had a tall stature, normal intelligence and testosterone levels, and did not exhibit aggressive behaviour.…”